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Abstract
Background. The Patient Health Questionnaire (PHQ-9), the Beck Depression Inventory
(BDI-II) and the Generalised Anxiety Disorder Assessment (GAD-7) are widely used in
the evaluation of interventions for depression and anxiety. The smallest reduction in depres-
sive symptoms that matter to patients is known as the Minimum Clinically Important
Difference (MCID). Little empirical study of the MCID for these scales exists.
Methods. A prospective cohort of 400 patients in UK primary care were interviewed on four
occasions, 2 weeks apart. At each time point, participants completed all three questionnaires
and a ‘global rating of change’ scale (GRS). MCID estimation relied on estimated changes in
symptoms according to reported improvement on the GRS scale, stratified by baseline severity
on the Clinical Interview Schedule (CIS-R).
Results. For moderate baseline severity, those who reported improvement on the GRS had a
reduction of 21% (95% confidence interval (CI) −26.7 to −14.9) on the PHQ-9; 23% (95% CI
−27.8 to −18.0) on the BDI-II and 26.8% (95% CI −33.5 to −20.1) on the GAD-7. The cor-
responding threshold scores below which participants were more likely to report improvement
were −1.7, −3.5 and −1.5 points on the PHQ-9, BDI-II and GAD-7, respectively. Patients with
milder symptoms require much larger reductions as percentage of their baseline to endorse
improvement.
Conclusions. An MCID representing 20% reduction of scores in these scales, is a useful guide
for patients with moderately severe symptoms. If treatment had the same effect on patients
irrespective of baseline severity, those with low symptoms are unlikely to notice a benefit.
Funding. Funding. National Institute for Health Research.
Introduction
Depression is a common reason for consultation in primary care (McManus et al., 2014) and a
major public health problem. Clinicians are faced with the difficulty of making treatment recom-
mendations for patients they see in primary care based upon evidence from studies that used assess-
ments for depressive symptoms that were developed primarily for research purposes. Deciding what
constitutes a clinically important treatment effect for those research assessments is therefore essen-
tial for interpreting the results of clinical research and designing randomised trials.
The minimum clinically important difference (MCID) provides a measure of the smallest
change in an outcome that is perceived as important to patients. This must be determined, to
understand the clinical utility of therapies intended to improve subjective outcomes.
The UK National Institute for Health and Care Excellence (NICE) proposed a reduction of
three points on the Hamilton Depression Rating Scale as clinically important, but this was
based solely on the opinion of an expert group (Kendrick and Pilling, 2012). Others have
used approaches that rely upon the error of measurement of the scales. Clinician ratings of
improvement have also been frequently used in depression research but none of these
approaches incorporates the patient’s perspective (Leucht et al., 2013).
Clinicians and policy makers give more emphasis on patients’ perspectives in the evaluation
of interventions and public health policies. It is therefore important to establish an MCID
anchored in the experiences and perceptions of patients (Tubach et al., 2012; Hinman et al.,
2014). In previous work, we have investigated the MCID for the Beck Depression Inventory
(BDI-II) from the perspective of the patient (Button et al., 2015). Using a Global Rating of
Change Scale (GRS), patients were asked whether they felt better, the same or worse since
they were last seen and the MCID was calculated as the minimum change in depression scores
associated with reporting feeling ‘better’.
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The current study further develops the previous approach. The
aim was to estimate the MCID for the BDI-II, PHQ-9 and GAD-7
scales. It studies a sample of primary care patients who have been
consulting about symptoms of depression and anxiety with broad
inclusion criteria to better reflect the population seeking help and
including patients with low levels of symptoms. We planned to
simply observe spontaneous changes in patients’ scores as patients
will be at all stages of their treatment and we did not provide any
intervention ourselves.
We have extended our previous work in several other ways.
Firstly, we include the PHQ-9 and GAD-7 that are frequently
used in research and are the standard outcome measures in
Improving Access to Psychological Therapies (IAPT) services.
Secondly, we have used a more flexible method of analysis to
allow comparisons between those reporting improvements against
those reporting ‘feeling the same’, over multiple waves. Our pre-
vious research merged the latter group with those ‘feeling
worse’. Finally, we have taken three different approaches to esti-
mate the MCID: the mean change for those ‘feeling better’, the
mean difference in change between ‘feeling better’ and ‘feeling
the same’, and the threshold value below which participants are




The sample was recruited from primary care surgeries in three UK
sites (Bristol, Liverpool, and York) between February 2013 and
April 2014. This study was part of the PANDA programme
(NIHR programme ‘What are the indications for Prescribing
ANtiDepressAnts that will lead to clinical benefit?’; NIHR
Programme Grant: RP PG 0610 10048). One of the primary
objectives of this element of the programme was to estimate the
MCID for measures of depression by assembling a pragmatic
and contemporary cohort of patients seeking help in primary
care with a broad range of depression symptom severity. As anx-
iety symptoms are often co-morbid with depression and no NICE
guideline addresses such presentations, the study also collected
data on a measure of generalised anxiety, the GAD-7, enabling
us to explore the MCID for this measure (Kendrick and Pilling,
2012).
Computerised records at collaborating general practices at each
site were searched to identify people who had reported depressive
episodes, depressed mood, depressive symptoms, or a major
depressive episode in the past year. Individuals were included if
they were aged between 18 and 74 years, treated or not treated
with antidepressants, and referred or not referred to IAPT ser-
vices. We excluded people who: were diagnosed with bipolar dis-
order, psychosis, or an eating disorder; had alcohol or substance
use problems; were unable to complete study questionnaires; or
were 30 weeks or more pregnant. Overall, 7721 patients were
sent an information letter in the post and 1470 (19%) replied.
Of these, 821 were willing to be contacted, 23 (3%) of whom
were ineligible. The remaining 798 were contacted to arrange an
interview, and 563 consented to take part in the cohort study.
Data on our measures were collected at four time points, each
approximately 2 weeks apart so that participants were in the study
for 6 weeks between baseline or time 1 and time 4. At time one,
559 people provided data (four could not be contacted), with cor-
responding figures at follow-ups two, three and four of 476 (85%),
443 (79%) and 430 (77%) respectively. In total, 400 (72%) parti-
cipants provided data at each of the four follow-ups and were
included in our analyses. Participants with missing data at one
or more follow-ups were excluded. Participation and attrition
rates are similar to those encountered in pragmatic clinical trials
in primary care (Richards et al., 2016; Lewis et al., 2019). We
found no evidence of a relationship between follow-up rates
and observed CIS-R scores or depression and anxiety symptoms
at baseline.
Interviews were conducted at the participant’s home or GP
surgery. All participants provided written informed consent and
ethical approval was obtained from National Research Ethics
Service Committee South West-Central Bristol (REC No:12/SW/
0267). The authors assert that all procedures contributing to
this work comply with the ethical standards of the relevant
national and institutional committees on human experimentation
and with the Helsinki Declaration of 1975, as revised in 2008.
The recruitment of participants is irrespective of the treatment
they are receiving and the duration of their treatment. We relied
therefore upon spontaneous changes in symptoms for our
analyses.
Measures
Beck Depression Inventory–II (BDI-II)
The BDI-II (Beck et al., 1996) is a self-report measure of the
severity of depressive symptoms, consisting of 21 items, each
assessed using a 4-point scale ranging from 0 to 3. Possible scores
range from 0 to 63. Higher scores indicate greater severity of
depressive symptoms. Participants were asked about the previous
2 weeks.
Patient Health Questionnaire (PHQ-9)
The PHQ-9 (Kroenke and Spitzer, 2002) is a self-report measure
of the severity of depressive symptoms, consisting of nine items
each with a 4-point scale ranging from ‘Not at all’ (0) to
‘Nearly every day’ (3). Possible scores range from 0 to 27 and
higher scores indicate greater severity of depressive symptoms.
The PHQ-9 asked about the previous 2 weeks.
Anxiety
The Generalised Anxiety Disorder Assessment (GAD-7)
(Spitzer et al., 2006) was used to measure anxiety at each time
point. The GAD-7 is a self-report measure of generalised anxiety
symptoms consisting of seven items, each assessed using a
4-point scale ranging from ‘Not at all’ (0) to ‘Nearly every day’
(3). Possible scores range from 0 to 21. Higher scores indicate
greater severity of anxiety and questions were asked about the
previous 2 weeks.
Global rating of change scale
The global rating of change scale is a self-report measure of sub-
jective well-being over time, asking participants: ‘Compared to
when we last saw you 2 weeks ago, how your moods and feelings
have changed?’. The five possible responses were: ‘I feel a lot bet-
ter’ (1), ‘I feel slightly better’ (2), ‘I feel about the same’ (3), ‘I feel
slightly worse’ (4), ‘I feel a lot worse’ (5). Participants completed
two global rating of change scales (separated by other
2 Daphne Kounali et al.
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questionnaires) at each time point, to assess reliability (Kamper
et al., 2009; Robinson et al., 2017).
Clinical Interview Schedule-Revised (CIS-R)
The CIS-R (Lewis et al., 1992) is a fully structured self-
administered computerised assessment of common mental disor-
ders that have been extensively used in community samples.
Participants were assessed using the CIS-R at baseline or time 1
only. The thresholds used (0-11/12-19/20+) were those pre-
specified in the protocol for the subsequent PANDA trial
(Salaminios et al., 2017).
Demographics
Demographic variables were measured at baseline using a self-
administered computerised assessment. These were age, gender,
ethnicity, employment status, financial status and education level.
Current antidepressant use
A short self-report measure was used to assess current medication
use at each time point. Participants were asked whether they were
currently taking antidepressants.
Statistical analyses
Accounting for baseline severity
We previously found that MCID on the BDI-II in absolute terms
varied according to baseline severity, with larger MCID estimates
at higher levels of severity (Button et al., 2015). Stratification by
baseline CIS-R groupings is motivated by the desire to examine
the potential dependence of the MCID on baseline severity.
CIS-R stratification is attractive statistically as it is highly corre-
lated with all measures and for this reason, increase precision in
estimates of change. In the current study, we also noted that the
relationship between the GRS and severity on the three measures
was different for participants with low (⩽11), medium (12–19)
and high (⩾20) total scores on CIS-R completed at time 1. We
also found that the mean initial PHQ-9 score in the group report-
ing ‘feeling the same’ is lower than in those reporting ‘feeling bet-
ter’ when baseline severity is low (CIS-R⩽11) (Table 1). In
contrast, in the high (CIS-R > 20) the mean initial PHQ-9 score
was lower in those reporting ‘feeling better’ compared to those
reporting ‘feeling the same’. These patterns were similar for all
outcomes (Tables 2 and 3).
The group of patients who report feeling the same is a mixture
of people who have high and low baseline scores. The reason why
those reporting ‘feeling the same’ at low baseline severity did not
experience any symptom change could be that they are not cur-
rently depressed. This is supported by our observations. Among
those reporting ‘feeling the same’ at baseline only 54% were on
current medication in the mild severity group whilst among
those reporting ‘feeling better’ 72% were on current medication.
As baseline severity increases, it becomes more likely that this
group report no change because of lack of improvement of their
symptoms. Thus, baseline CIS-R stratification provides a clinical
context for understanding baseline variability in scores. Using
the CIS-R also conferred the advantage of providing a measure
of baseline severity independent of the scales of interest.
Reliability of the global rating of change scale (GRS)
Reliability of the Global Rating of change scale was quantified using
the two repeated assessments completed by the patient within each
period. Levels of agreement for the GRS were estimated via the
(unweighted) Kappa coefficient (Landis and Koch., 1977). We
also assessed GRS reliability using the intra-class correlation
coefficient (Skrondal and Rabe-Hesketh. 2004). These calculations
were conducted using Stata version 15 (StataCorp, 2015).
Change in BDI-II, PHQ-9 and GAD-7 scores – modelling
We used Bayesian hierarchical regression models to estimate the
changes in symptom scores measured by the three scales
(BDI-II and PHQ-9 and GAD-7) and over three waves (times 1
and 2, 2 and 3 and 3 and 4). These estimates were allowed to
vary according to GRS groupings and baseline CIS-R score
(Zimprich, 2010; Verkuilen and M, 2012). Estimates of changes
were based on their respective contemporaneous GRS ratings at
each wave. The baseline GRS informed estimates of initial scores
specific to each CIS-R group. Our estimates of MCID were based
upon the GRS at time 2, 3 and 4 that were combined with changes
in scores between time 1 and 2, 2 and 3 and 3 and 4, respectively.
We can then arrive at estimates across those time periods of the
initial score and changes in score according to GRS category.
We carried out comparisons of different models using various
distributional assumptions and link functions and found the
beta-regression to perform best in terms of overall model fit cri-
teria (DIC) (Spiegelhalter et al., 2002).
A detailed description of the model specifics is provided in
online Appendix 1. We carried out model fitting, model compar-
isons and post-estimation calculations using the WinBUGS statis-
tical software (Spiegelhalter et al., 2007).
Given the small sample sizes in some GRS response options,
these were amalgamated as follows: ‘I feel a lot better’ (1) and ‘I
feel slightly better’ (2) under the revised category ‘Feeling better’;
‘I feel slightly worse’ (4) and ‘I feel a lot worse’ (5) under the
revised category: ‘Feeling worse’. This amalgamation did not con-
fer noticeable loss of information for the comparisons of interest,
since 72% of responses below GRS level 2 were endorsing level 2
and 77% of response above level 4 were endorsing level 4 without
considering any other breakdown in baseline severity (Appendix 1).
We have included the data on all three GRS categories for the sake
of completeness.
We express differences in terms of proportional as well as
absolute scores using standard post-estimation calculations. The
variability in the distribution of change in the different groups
was also estimated.
Receiver operating characteristic (ROC) analysis
We estimated the threshold value of change that corresponds to
the maximum improvement in sensitivity over chance.
The ROC parameters required for the derivation of the MCID
and sensitivity and specificity determination were based on calcu-
lations for functions of the parameters estimated from the above
regression models, assuming approximate normality (Appendix 1).
In Table S1.1 (Appendix 1), we present uncertainty estimates
of the sensitivity and specificity at the optimal threshold.
Statistics relevant to the determination of the optimal threshold
are presented in Table S1.2, along with standardised estimates
of change in Table S1.3.
Psychological Medicine 3
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Results
Sample characteristics
We restricted the analysis to the 400 patients who had complete
data for all four time points. No baseline differences between
excluded and included patients were apparent in the outcomes
under study or their demographics. Demographic and clinical
characteristics are shown in Table S2.1 (Appendix 2).
Participants were aged 17–71 years (mean = 48.7), and the major-
ity were female, white, married, and employed. Roughly a third of
participants had completed higher education. Just under half of
participants met ICD-10 criteria for major depressive disorder
at baseline. The vast majority reported using antidepressants at
each time point.
Descriptive statistics of the distribution of GRS scale over
time overall as well as stratified by CIS-R are presented in
Appendix 2 (Table S2.2, Figure S2.1). The CIS-R score was
strongly associated with all self-rated scales BDI-II, PHQ-9 and
GAD-7, with correlations at baseline of 0.82, 0.78 and 0.77,
respectively. There were no changes in GRS scores over time
beyond that expected by chance.
Test-retest reliability of the GRS
Levels of agreement for the GRS were found to be substantial or
excellent, with kappa values of 0.73, 0.84, 0.86 and 0.81 for base-
line, first, second and third visits, respectively. The intraclass cor-
relation coefficients were: 0.95 (95% CI 0.94–0.96) at baseline;








Mean 95% CI Mean 95% CI Mean 95% CI
Baseline CIS-R Initial PHQ9
≤11 36 4.15 (3.07 5.39) 78 2.66 (2.15 3.26) 9 6.08 (3.38 9.59)
12–19 25 7.97 (6.08 10.17) 58 8.75 (7.51 10.11) 9 11.06 (7.49 15.25)
20+ 32 12.20 (9.91 14.60) 117 15.01 (13.98 16.07) 36 17.23 (15.11 19.09)
Change in previous 2 weeks
≤11 −1.00 (−1.45 −0.63) −0.28 (−0.48 −0.09) 0.75 (0.15 1.41)
12–19 −1.66 (−2.28 −1.11) −0.83 (−1.33 −0.32) 0.45 (−0.20 1.12)
20+ −2.38 (−2.85 −1.88) −0.66 (−1.05 −0.26) 0.27 (−0.15 0.72)
Change in previous weeks as a proportion of initial PHQ9 score
≤11 −0.24 (−0.31 −0.17) −0.10 (−0.17 −0.03) 0.13 (0.03 0.24)
12–19 −0.21 (−0.27 −0.15) −0.09 (−0.15 −0.04) 0.04 (−0.02 0.10)
20+ −0.20 (−0.24 −0.15) −0.04 (−0.07 −0.02) 0.02 (−0.01 0.04)
(*)N denotes sample size at baseline for each group. Detailed account of the number of participants contributing to the estimates in each visit is given in Appendix 2 Figure S2.1.
Table 2. Estimate initial and change in BDI-II score (previous 2 weeks) according to patient reported Global ratings and time 1 CIS-R
Global Rating
Scale
Feeling better Feeling same Feeling worse
N(*) Mean 95% CI N(*) Mean 95% CI N(*) Mean 95% CI
Baseline CIS-R Initial BDI
≤11 36 9.67 (7.52 12.02) 78 6.24 (5.29 7.27) 9 11.74 (7.07 17.37)
12–19 25 14.68 (11.32 18.78) 58 15.94 (13.69 18.26) 9 16.54 (10.99 22.76)
20+ 32 22.25 (18.80 26.07) 117 26.99 (24.77 29.13) 36 31.68 (28.05 35.50)
Change per 2 weeks
≤11 −2.97 (−3.89 −2.19) −1.28 (−1.67 −0.93) 0.11 (−0.79 1.02)
12–19 −3.36 (−4.46 −2.49) −1.61 (−2.31 −0.93) −0.12 (−1.00 0.78)
20+ −4.32 (−5.16 −3.51) −1.57 (−2.20 −0.94) 0.14 (−0.61 0.93)
Change per 2 weeks as a percentage of initial BDI score
≤11 −0.31 (−0.36 −0.25) −0.21 (−0.25 −0.16) 0.01 (−0.07 0.09)
12–19 −0.23 (−0.28 −0.18) −0.10 (−0.15 −0.06) −0.01 (−0.06 0.05)
20+ −0.20 (−0.23 −0.16) −0.06 (−0.08 −0.03) 0.01 (−0.02 0.03)
(*)N denotes sample size at baseline for each group. Detailed account of the number of participants contributing to the estimates in each visit is given in Appendix 2 Figure S2.1.
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0.98 (0.97–0.99) at the first visit; 0.92 (0.90–0.94) at the second;
and 0.99 (0.98–0.99) at the third.
Change in BDI-II, PHQ-9 and GAD-7 over time for each grouping
of the global rating of change (GRS) scale
In Table 1, we present estimated mean initial levels and changes
in mean scores in both absolute and proportional terms for
each CIS-R severity group and GRS group on the PHQ-9.
Tables 2 and 3 provide the same estimates for the BDI-II and
GAD-7. The initial scores vary depending upon the CIS-R groups.
The changes required for people to report ‘feeling better’ increase
with baseline severity (Figures S3.1-S3.3, Appendix 3). It is also
noteworthy that the increases seen for those ‘feeling worse’ were
not as large as the reductions in those reporting ‘feeling better’.
No differences in the estimated percentage changes for those
reporting ‘feeling better’ was found across CIS-R severity groups,
for all outcomes (Tables 1–3).
Participants who reported ‘feeling the same’, also experienced
reductions in score on all outcomes, though smaller than those
who reported ‘feeling better’. In Table 4 we have estimated the dif-
ference in the changes reported by those who report ‘feeling bet-
ter’ and those who report ‘feeling the same’, in absolute scores as
well as a percentage of their respective baseline scores. In general,
the differences between ‘feeling better’ and the same became lar-
ger as the CIS-R severity increased.
ROC analysis
In Table 5, we present our estimates from the ROC analysis. The
ROC analysis selects the optimal threshold below which partici-
pants are more likely to report ‘feeling better’ rather than ‘feeling
the same’. The mean change in the group reporting ‘feeling better’
(see Tables 1–3) is a good approximation for the optimal thresh-
old when the baseline symptom severity is moderate and high for
all three instruments. However, when the depression severity is
low, the optimal threshold needs to be considerably lower than
the mean change to optimise the discrimination between the
two groups (Figure Appendix 2: S2.2a-S2.2c).
These results illustrate that at lower levels of depression severity
participants are less good at discriminating between ‘feeling better’
and ‘feeling the same’ for all three scales. The optimal threshold
was estimated at 2 points and was not greatly affected by baseline
severity for the PHQ-9. The threshold score for the BDI-II was 5
points at low baseline severity – higher than the 4 points for mod-
erate and high CIS-R. Finally, the threshold score for GAD-7 was 2
points for low and moderate CIS-R and 1 point for high CIS-R at
time 1 (Table 5). The absolute change was similar across the three
severity bands, but the percentage change increased in the least
severe band. This is true for all measures.
At low baseline CIS-R, the sensitivity (Table 5) was 35%, 36%
and 32% for PHQ-9, BDI-II and GAD-7 respectively, representing
the proportion who reported they felt better and had experienced
reductions larger than the threshold score. At higher baseline
CIS-R, the patients who reported improvement had much higher
chances (60% or more) to show reductions larger than the thresh-
old score in all scales. The data on standard deviations and stan-
dardised change, further illustrates that the reduction in MCID at
lower severity is due to reduced sensitivity to change and
increased variance (Appendix 1: Table S1.2 and S1.3).
Discussion
We have estimated the minimally clinically important difference
using a patient-centred approach for three commonly used scales
employed to assess depression and anxiety. We have estimated the
reduction in scores during the previous 2 weeks in those who
reported ‘feeling better’. We then estimated the difference between
‘feeling better’ and ‘feeling the same’ in terms of the reduction of
scores.
We also formulated the problem as trying to distinguish
between ‘feeling better’ and ‘feeling the same’ using ROC analysis
to arrive at the threshold value that provides maximal separation
and accounts for the increased variability of scores at both ends of
these scales.








Mean 95% CI Mean 95% CI Mean 95% CI
Baseline CIS-R Initial GAD-7
≤11 36 3.05 (2.26 4.01) 78 1.92 (1.51 2.37) 9 5.24 (3.07 7.88)
12–19 25 5.62 (4.14 7.26) 58 6.23 (5.25 7.33) 9 5.24 (3.02 7.82)
20+ 32 9.02 (7.37 10.93) 117 11.12 (10.18 11.98) 36 13.97 (12.38 15.39)
Change per 2 weeks
≤11 −0.81 (−1.18 −0.50) −0.27 (−0.44 −0.11) 0.86 (0.27 1.54)
12–19 −1.50 (−2.04 −1.03) −0.53 (−0.92 −0.11) 0.00 (−0.47 0.50)
20+ −1.56 (−1.96 −1.16) −0.42 (−0.76 −0.08) 0.67 (0.28 1.06)
Change per 2 weeks as a percentage of baseline GAD7 score
≤11 −0.26 (−0.34 −0.19) −0.14 (−0.21 −0.06) 0.17 (0.05 0.30)
12–19 −0.27 (−0.34 −0.20) −0.09 (−0.15 −0.02) 0.00 (−0.09 0.10)
20+ −0.17 (−0.22 −0.13) −0.04 (−0.07 −0.01) 0.05 (0.02 0.08)
(*)N denotes sample size at baseline for each group. Detailed account of the number of participants contributing to the estimates in each visit is given in Appendix 2 Figure S2.1.
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In the lowest severity group, average reductions experienced by
those reporting ‘feeling better’ were much smaller (around 20–
30%) than the optimal thresholds required to discriminate
between ‘feeling better’ and ‘feeling the same’ (between 48%
and 71%). This was true for all three scales. The marked increase
of threshold in percentage terms is due to the increased variability
of change, particularly in those feeling better at lower baseline
severity and this makes discrimination more difficult. At low
scores, patients will only be able to detect a relatively large pro-
portionate change.
In our previous work, we found evidence that viewing the
MCID as a proportion led to a more constant value over the
severity range (Button et al., 2015). However, this was based on
analyses informed by randomised controlled trials (RCTs)
which excluded patients below a certain threshold score and simi-
lar distributions of baseline scores on the BDI scale. In this study
with a sample with lower severity scores, it is apparent that there
is still an increase in MCID in proportional terms at lower levels
of severity, even if the absolute levels are relatively constant. It is
perhaps unsurprising that those with low scores will find it more
difficult to distinguish between ‘feeling the same’ and ‘feeling
better’. The likely explanation is that the reliability of change
for these scales is also dependent on the baseline.
It is striking that there are many similarities in how the differ-
ent scales behave in relation to self-reported improvement.
Previous meta-analytic work evaluating the relative responsive-
ness of eight scales (6 depression and 2 quality of life) also
found little difference between scales capturing change caused
by treatment (Kounali et al., 2016). The study included a broad
range of different treatments and even though the absolute values
of the scales differed, the pattern of results was similar and the
proportionate changes seemed comparable.
Strength and limitations
This is the first study on establishing multiple MCIDs from a large
contemporary cohort drawn from a population seeking help for
their symptoms in primary care in the UK. In contrast to our pre-
vious study that used data from RCTs, this sample was not selected
according to severity criteria. Our approach allowed for a realistic
assessment of the distribution of change, which is implicated in
the determination of the optimal threshold. The results enhance
Table 4. Estimated difference in change between the group reporting feeling better and the group reporting feeling the same in absolute scores and % from their
respective initial scores for PHQ9, BDI-II and GAD-7 scales
Baseline Severity
CIS-R 0–11 CIS-R 12–19 CIS-R 20+
Mean 95% CI Mean 95% CI Mean 95% CI
Outcome Difference in change
PHQ9 −0.73 (−1.13 −0.40) −0.85 (−1.45 −0.31) −1.70 (−2.18 −1.24)
BDI −1.66 (−2.54 −0.89) −1.76 (−2.74 −0.79) −2.77 (−3.61 −1.94)
GAD-7 −0.54 (−0.88 −0.24) −0.99 (−1.53 −0.49) −1.15 (−1.57 −0.72)
Difference in % change
PHQ9 −0.14 (−0.22 −0.07) −0.12 (−0.18 −0.06) −0.15 (−0.19 −0.11)
BDI −0.10 (−0.16 −0.04) −0.13 (−0.18 −0.08) −0.14 (−0.17 −0.10)
GAD-7 −0.12 (−0.21 −0.04) −0.18 (−0.26 −0.11) −0.14 (−0.18 −0.09)
Table 5. Estimated threshold score for discriminating between feeling better and feeling the same for the PHQ9 BDI-II and GAD-7 scales according to baseline








% of baseline Spec(1) Sens(2)
AUC(3)
Mean (2.5% 97.5%)
PHQ9 ≤11 −2.0 48.2 (65.1 37.1) 0.78 0.35 0.57 (0.54 0.60)
12–19 −1.7 21.3 (27.9 16.7) 0.59 0.51 0.57 (0.53 0.62)
20+ −2.4 19.7 (24.2 16.4) 0.63 0.52 0.61 (0.58 0.64)
BDI ≤11 −5.0 51.7 (66.6 41.6) 0.80 0.36 0.59 (0.55 0.63)
12–19 −3.5 23.8 (30.9 18.6) 0.65 0.50 0.60 (0.55 0.65)
20+ −4.4 19.7 (23.4 16.9) 0.65 0.51 0.61 (0.58 0.65)
GAD-7 ≤11 −2.2 72.1 (97.3 54.8) 0.78 0.32 0.55 (0.53 0.59)
12–19 −1.5 26.7 (36.2 20.7) 0.51 0.62 0.59 (0.55 0.64)
20+ −0.8 8.9 (10.9 7.3) 0.55 0.54 0.57 (0.54 0.59)
(1)Probability (improvements/reductions smaller than MCID when feeling the same).
(2)Probability (improvements/reductions larger than MCID when feeling better).
(3)Probability the improvement (reduction) in scores for a randomly chosen patient drawn from those reporting feeling the same is smaller than for a randomly chosen person drawn from
those reporting feeling better.
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our earlier work by extending it to lower severities of symptoms and
to include other commonly used outcome measures, the PHQ-9
and GAD-7. In this study, as in our previous work, we are assuming
that the MCID is the same irrespective of whether the change results
from treatment or is spontaneous. Nevertheless, in this study, we
acknowledge that we had little information on treatments and
how this might have affected MCID estimates.
Despite the size of this cohort, the number with low CIS-R base-
line severity who report ‘feeling better’ at baseline is still rather small
(n = 36), so some of our estimates lacked precision. Our method also
relied on the use of self-reported improvement. It remains unclear
how patients’ perceptions of change can inform therapeutic signifi-
cance, but it is certainly an aspect of this. Using self-reported change
as a ‘gold standard’ has good face validity (Malpass et al., 2016) and
qualitative findings support its use. Yet our results indicate areas
where our understanding of how patients perceive and retrospect-
ively recall change requires further research. For example, the find-
ing that people who reported ‘feeling the same’ also had reductions
in symptoms is not well understood (Robinson et al., 2017). One
possible explanation is that the patient’s GRS is likely to include
constructs additional to those measured by the disease-specific
scales, so a perfect correlation is not expected. Research in
health-related quality of life has also found that retrospective mea-
sures of the patient’s view of change is sensitive to change in disease-
specific scales and correlates strongly with patient’s satisfaction with
change but is not concordant with repeated current assessments of
patients’ experience of change (Fischer et al., 1999). This literature
also presents evidence that those with less severe symptoms at base-
line have smaller change scores over time; thus, variability in base-
line severity may reduce the strength of association between change
scores and the GRS (Stucki et al., 1996). It is also noteworthy that
there was a marked asymmetry in this sample such that feeling
worse was not associated with such large changes as ‘feeling better’.
The reasons for this are unknown.
Comparative elicitation of improvement using clinician-rated
scales could have been interesting. Self-administered scales are
used clinically in primary care and psychological services
(IAPT). Even though there is much pharmacological data using
the HAMD, it is not used in routine clinical practice. Our choice
of using the patient’s GRS was influenced by a wider trend where
research studies will have to use the measures used in clinical
practice.
There are several reasons why there might be disagreement
between the GRS and the changes in the depression and anxiety
scales. For example, someone might report feeling better because
their anxiety symptoms have improved rather than their depres-
sive symptoms. We have carried out a study to look at this and
other factors (Hobbs et al., 2020). In this paper, we are estimating
average MCIDs and the strong association between depression
and anxiety should not affect our interpretation of the results.
For example, if an intervention leads to an improvement of anx-
iety symptoms more than depressive symptoms, this should be
reflected in the treatment effect exceeding the MCID for anxiety
but not depressive symptoms. Therefore, calculating separate
MCIDs for the different scales will help their use clinically.
Individual expectation is an important determinant of a
patient’s view of their condition, and new medication prescription
could raise expectations. However, conversely, it is also true that a
prescription of longer duration that fails to produce a benefit can
lead to lower expectations. In this study, most of the patients had
already been prescribed antidepressants (88%). We do not have
data to distinguish those with a newly prescribed medication.
Even if such data were available, much larger sample sizes
would be required to examine their impact on MCID estimates.
Furthermore, in our study, we were primarily interested in retro-
spective judgements about change rather than future expectations
about improvement.
There are many factors that may influence an individual
patient’s views of improvement. We have previously reported
that patients with more severe anxiety are less likely to report
improvement even after controlling for depressive symptoms
(Hobbs et al., 2020). In principle, factors that might influence
MCID could be incorporated as interaction effects in our model
for change in self-rated scores and, if present, these could impact
on MCID estimates. However, more individualised MCIDs would
require a substantially larger sample size to have the power to
detect any interactions.
Implications
We provide different MCID estimates for depression and anxiety
scales that are widely used in both primary care and psychological
services. These estimates could help clinicians interpret the rele-
vance of changes in the instrument scores they use. They can
be used for an individual patient to estimate changes that are
likely to be beneficial. The MCID can be used to compare treat-
ments when accurate predictions of the patients’ future outcomes
are available. This way of using the MCID rests on a counterfac-
tual argument in which the future potential outcome of a patient
on an active treatment can be contrasted with their future out-
come on a comparator. Our MCID estimates could be considered
as the minimum difference and allow clinical relevance to be
determined in relation to the treatment effects and their confi-
dence intervals from RCTs and meta-analyses. It is also important
that the power of clinical trials is sufficient to detect the MCID.
The MCID enables clinicians to interpret the effectiveness of
treatments in RCTs in primary care beyond statistical significance.
In our previous paper (Button et al., 2015) we suggested that
the MCID for the BDI-II was about 17.5%. At the moderate
and higher severities in this study, we again find that roughly a
20% change for the PHQ-9, BDI-II and GAD7 corresponded to
an MCID. However, at lower severities, this was no longer the
case. Unsurprisingly perhaps, patients needed larger percentage
changes at low scores to be able to endorse improvement. Our
results indicate that even if treatment effects are similar in those
with less severe symptoms, it is much less likely that these patients
will experience a benefit. This also implies that treatment effects
from RCTs may overestimate the effectiveness of treatment for
patients with mild symptoms.
The analysis here is based upon the patient identifying an
improvement in symptoms retrospectively. This is a slightly dif-
ferent idea than that of ‘clinical importance’ underlying the
MCID concept. It seems reasonable to conclude that if someone
has not noticed improvement there has not been a clinically
important benefit. In contrast, it is possible someone has noticed
an improvement, but this is not necessarily of clinical importance.
In that sense, our approach provides a minimum above which
treatment effects can be judged.
There is currently much controversy about the benefits or
otherwise of antidepressant treatment, especially in those with
less severe symptoms. Our approach provides a basis on which
to power clinical studies and help clinicians interpret the evidence
and judge whether a treatment is likely to benefit a patient treated
in primary care. More empirical studies considering patients’
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perspectives and using large databases of electronic health records
are needed to refine MCIDs in specific decision contexts along-
side predictions of patients’ outcomes. Different MCIDs are
required to support different decisions to initiate, monitor or dis-
continue treatment whilst accounting for individual patient char-
acteristics as well as patient preference.
Supplementary material. The supplementary material for this article can
be found at https://doi.org/10.1017/S0033291720003700
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